Cogent surges on trial win for blood disorder drug

Cogent Biosciences

07/07/2025 13:03

** Shares of drug developer Cogent Biosciences COGT.O rise 19.4% to $9.05 premarket

** Co says its drug, bezuclastinib, showed a statistically significant reduction in symptoms in patients with mastocytosis, a type of blood disorder

** Mastocytosis is a disease where the body makes too many of a type of white blood cell called mast cells, which build up in places like the bone marrow, skin or organs

** COGT expects to file a marketing application for the treatment by the end of 2025

** Up to last close, stock down 2.8% YTD

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))